Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Arch Biopartners Inc. (V:ARCH)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ARCH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 30, 2020 09:21 ET
Arch Biopartners Closes Non-Brokered Private Placement
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has closed the non-brokered private...
Read full article
Jun 24, 2020 08:41 ET
Arch Biopartners Arranges Non-Brokered Private Placement
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has arranged a non-brokered private...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.31
--
--
Price to Sales - TTM
552.65
10.96
8.60
Price to Book - most recent quarter
--
4.91
2.67
Price to Cash Flow per share - TTM
--
19.25
12.30
Price to Free Cash Flow per share - TTM
--
54.78
22.04
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 30, 20202,873-51,397
Jun 15, 202054,27051,843
May 31, 20202,427-4,715
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Arch Biopartners Inc. is a portfolio-based biotechnology company. The Company is focused on the development of technologies that make a medical or commercial impact. Its technology platforms include AB569, MetaBlok, Arch Inflammation, Borg and MetaMx. AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and urinary tract. MetaBlok is a drug candidate targeting sepsis, cancer metastasis and inflammation based diseases. Arch Inflammation is a treatment for chronic kidney and bowel diseases caused by non-infectious inflammation. Arch Inflammation is focused on developing anti-inflammatory small molecules that target proteins in the innate immune system. Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation. MetaMx are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The Company has not generated any revenues.

See business summary

 

Twitter

Search (past week) for $ARCH.CA ARCH.V